The FDA has granted Cognoa marketing authorization of Cognoa's autism diagnosis aid. Introducing Canvas Dx.

Cognoa expects to begin making Canvas Dx available in the U.S. later in 2021.

Stay Informed

Indications for Use

The Cognoa ASD Diagnosis Aid is intended for use by healthcare providers as an aid in the diagnosis of Autism Spectrum Disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only).

Precautions, Warnings

The Device is intended for use by healthcare professionals trained and qualified to interpret the results of a behavioral assessment examination and to diagnose ASD.

The Device is intended for use in conjunction with patient history, clinical observations, and other clinical evidence the HCP determines are necessary before making clinical decisions. For instance, additional standardized testing may be sought to confirm the Device output, especially when the Device result is not Positive or Negative for ASD.

Cognoa ASD Diagnosis Aid is intended for patients with caregivers who have functional English capability (8th grade reading level or above) and have access to a compatible smartphone with an internet connection in the home environment.

The Device may give unreliable results if used in patients with other conditions that would have excluded them from the clinical study. Among those conditions are the following:

  • Suspected auditory or visual hallucinations or with prior diagnosis of childhood onset schizophrenia.
  • Known deafness or blindness.
  • Known physical impairment affecting their ability to use their hands.
  • Major dysmorphic features or prenatal exposure to teratogens such as fetal alcohol syndrome.
  • History or diagnosis of genetic conditions (such as Rett’s syndrome or fragile X).
  • Microcephaly.
  • History or prior diagnosis of epilepsy or seizures.
  • History of or suspected neglect.
  • History of brain defect injury or insult requiring interventions such as surgery or chronic medication.

The Device evaluation should be completed within 60 days of the time it is prescribed because neurodevelopment milestones change rapidly in the indicated age group.

Stay Informed

Privacy Policy © Cognoa 2021